Mota-Zamorano Sonia, Luna Enrique, Garcia-Pino Guadalupe, González Luz M, Gervasini Guillermo
Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain.
Service of Nephrology, Badajoz University Hospital, Badajoz, Spain.
Mol Genet Metab Rep. 2020 Sep 12;25:100648. doi: 10.1016/j.ymgmr.2020.100648. eCollection 2020 Dec.
We aimed to examine whether combined donor/recipient variants in the leptin receptor () and adiponectin () genes may affect outcomes in renal transplantation.
A total of 233 donors and their corresponding 307 recipients were genotyped for rs1805094, rs1137100 and rs1137101, and rs1501299 and rs224176. Combined donor/recipient genetic scores were created to investigate associations with delayed graft function (DGF), graft loss and estimated glomerular filtration rate (eGFR).
Recipients whose donors carried variant alleles of and rs1137101 had lower risk of DGF [OR = 0.48 (0.24-0.97), = 0.040] and [OR = 0.47 (0.23-0.95), = 0.035], respectively. In addition, rs1137101 also showed an inverse association with lower incidence of graft loss [OR = 0.44 (0.31-0.97), = 0.040]. The analysis of genetic scores of donor/recipients showed that again rs1137101 was inversely associated with both outcomes: OR = 0.46 (0.23-0.92), = 0.029 and OR = 0.45 (0.11-0.81), = 0.009, respectively. With regard to graft function, the T-allele of rs1501299 in the donor was related to higher eGFR values (75.26 ± 29.01 vs. 67.34 ± 25.39 ml/min for wild-type grafts, = 0.012). Higher combined genetic scores in this same polymorphism were also associated with better function (78.33 ± 31.87 vs. 68.25 ± 24.32 ml/min, = 0.018). Finally, eGFR values were similar between paired kidneys but they were different when comparing grafts with or without the rs1501299 T-variant (77.87 ± 26.50 vs. 69.27 ± 26.73 ml/min, = 0.016).
Our study has shown for the first time to our knowledge that variants in and genes of the donors and/or their combination with those in the recipients may affect the outcome of renal transplantation.
我们旨在研究瘦素受体()和脂联素()基因中供体/受体联合变异是否会影响肾移植的结果。
对总共233名供体及其对应的307名受体进行了基因分型,检测瘦素受体基因的rs1805094、rs1137100和rs1137101,以及脂联素基因的rs1501299和rs224176。创建供体/受体联合基因评分以研究与移植肾功能延迟(DGF)、移植肾丢失和估计肾小球滤过率(eGFR)的关联。
供体携带瘦素受体基因rs1137101变异等位基因的受体发生DGF的风险较低[比值比(OR)=0.48(0.24 - 0.97),P = 0.040],携带脂联素基因rs1137101变异等位基因的受体发生DGF的风险也较低[OR = 0.47(0.23 - 0.95),P = 0.035]。此外,rs1137101与较低的移植肾丢失发生率也呈负相关[OR = 0.44(0.31 - 0.97),P = 0.040]。对供体/受体基因评分的分析表明,rs1137101再次与这两个结果呈负相关:OR分别为0.46(0.23 - 0.92),P = 0.029和OR = 0.45(0.11 - 0.81),P = 0.009。关于移植肾功能,供体脂联素基因rs1501299的T等位基因与较高的eGFR值相关(野生型移植肾为75.26±29.01 vs. 67.34±25.39 ml/min,P = 0.012)。该相同多态性中较高的联合基因评分也与更好的肾功能相关(78.33±31.87 vs. 68.25±24.32 ml/min,P = 0.018)。最后,配对肾脏之间的eGFR值相似,但比较有或无rs1501299 T变异的移植肾时,eGFR值不同(77.87±26.50 vs. 69.27±26.73 ml/min,P = 0.016)。
据我们所知,我们的研究首次表明供体的瘦素受体和脂联素基因变异及/或其与受体基因变异的组合可能影响肾移植的结果。